GUIDELINES
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Practice Guideline (2022)
Evidence-based guidelines for the use of TKIs in adults with Philadelphia chromosome-positive or BCR-ABL-positive ALL (2014)
Canadian national consensus guidelines for naloxone prescribing by pharmacists (English, French 2020)
A Canadian guideline on the use of NGS in oncology (2019)
A Canadian Evidence-Based Guideline for the First-Line Treatment of FL (2014)
Evidence-based guidelines for the use of TKIs in adults with Philadelphia chromosome-positive or BCR-ABL-positive ALL (2014)
WHITE PAPERS
A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada (2023)
Monoclonal Antibodies as COVID-19 Prophylaxis Therapy in Immunocompromised Patient Populations (2023)
Management of B-cell Malignancies with BTKis: Nursing & Pharmacy Perspective (2023)
Management of Marginal Zone Lymphoma: A Canadian Perspective (2023)
Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective (2022)
A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies (2022)
A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia (2022)
Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective (2022)
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometroid tubal, Ovarian, and Primary Peritoneal Cancers (2022)
Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder (2021)
BTK inhibitors approved in Canada for CLL: Strategies for adverse event management (2021)
Canadian Perspective on Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable NSCLC (2021)
Bruton tyrosine kinase inhibitors for the frontline treatment of CLL (2020)
Canadian perspective on managing MM during the COVID-19 pandemic: Lessons learned and future considerations (2020)
Management of CLL in Canada during the coronavirus pandemic (2020)
Review of BTK inhibitors for the treatment of relapsed or refractory MCL (2019)
Multidisciplinary perspective on the SC administration of trastuzumab in HER2-positive breast cancer (2019)
Update on the SC administration of rituximab in Canadian cancer centres (2020)
Emerging therapies for the treatment of relapsed or refractory DLBCL (2019)
Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective (2018)
Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss (2017)
Use of minimal residual disease assessment in the treatment of CLL (2017)
A Canadian perspective on the SC administration of rituximab in NHL (2017)
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and MCL (2016)
Novel regimens prior to ASCT for the management of adults with relapsed/refractory NHL and HL (2016)
A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in CLL (2016)
Expanded-access trial of bendamustine in patients with rituximab-refractory indolent NHL or untreated CLL: BEND-ACT (2015)
Emerging therapies for the treatment of relapsed or refractory FL (2016)
REPORTS
Final_CGP_Report_Dec23.pdf
